Zorginstituut Nederland’s Lecanemab Healt...

By HEOR Staff Writer

February 18, 2026

Dutch Health Insurance Rejects Lecanemab Coverage Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basi...
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investmen...
NICE Endorses Dupilumab for Eosinophilic COPD Treatment
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
NICE Approves Seven Digital Cardiac Rehabilitation Technologies for Enhanced ...
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...